ERBB2 and breast carcinoma: The subjective mode of HER2 assessment and HER2 intratumoral heterogeneity in HER2-low breast cancer are other barriers with great influence on HER2-low assessment (Bianchi et al., 2015; Jensen et al., 2020; Zhang et al., 2020).